X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Mid caps buck the trend
Wed, 29 Aug 11:30 am

Indian equity markets continued to trade in the red during the last two hours of trade. Sectoral indices represented a mixed performance with IT and auto stocks leading the losses while healthcare and banking stocks managed some gains.

The BSE-Sensex is trading lower by 38 points and NSE-Nifty is trading lower by 15 points. However, BSE Mid Cap is currently up by 0.1%. BSE Small Cap is trading flat. The rupee is trading at 55.62 to the US dollar.

Steel stocks are trading weak led by Steel Authority of India Limited (SAIL) and JSW Steel. According to a leading financial daily, Tata Steel has raised its stake in Tata Sponge Iron to 51%. The steel company bought 11.26% stake through a voluntary open offer thereby increasing the stake from 39.74% to 51%. Total public shareholding in Tata Sponge iron is now 45.5% as compared to the previous 56.7%. We may recollect here that Tata Sponge Iron was set up as a joint venture between Tata Steel and the Industrial Promotion and Investment Corporation of Orissa Limited (IPICOL). However, in 1991, Tata Steel made it an associate company by buying out IPICOL's stake. In July this year, Tata Steel had launched a voluntary open offer at Rs 375 per share. The Tata company however has no plans to merge Tata Sponge with itself.

Pharma stocks are trading strong led by Glenmark Pharma and Ipca Labs. According to a leading financial daily, Wockhardt has received approval from US health regulator to sell generic ropinirole hydrochloride, which is used in the treatment of Parkinson's disease. The company has received US FDA approval for extended-release tablets in multiple strengths of 2mg, 4mg, 6mg, 8mg and 12mg containing ropinirole hydrochloride. Ropinirole's extended release tablet is the generic name for the brand Requip XL, marketed in the US by Glaxo SmithKline. Wockhardt will manufacture the extended release tablets of ropinirole at its facility in Aurangabad. The technology for the tablets was developed in-house. This is the sixth US FDA approval for Wockhardt in the past two weeks. Three of these have been for extended-release products.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Equitymaster requests your view! Post a comment on "Mid caps buck the trend". Click here!

  

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE SENSEX


Feb 23, 2018 09:53 AM

MARKET STATS